Keywords
How to Cite
Abstract
Aim. To evaluate a prognostic value of the surrogate molecular biological subtypes of breast cancer (BC) by the data of Arkhangelsk Regional Cancer Registry (ARCR) over the period 2010-2020.
Materials and methods. A continuous sampling of breast cancer patient records from the AOCR database was combined with immunohistochemical (IHC) data from the pathological database, including estrogen and progesterone receptors, Her2neu, and Ki67 levels. The surrogate molecular biological subtypes were determined based on the combination of these markers. Cancer-specific survival (CSS) and overall survival (OS) were assessed using the Kaplan-Meier methods and the life table method. The prognostic value of factors available in the registry database was assessed using Cox regression.
Results. 5 357 cases of BC were selected, and the surrogate subtype was determined in 3048 cases. The 5-year CSS rates for luminal A (LA), luminal B (LB), luminal B Her2neu-positive (LBHer2neu+), hormone receptor-negative Her2neu-positive (HR-Her2neu+), and triple-negative (TN) BC were 89.9 %, 78.8 %, 79.3 %, 65.2 %, and 66.7 %, respectively; 5-year OS rates were 80.2 %, 69.0 %, 72.4 %, 61.6 %, and 59.4 %, respectively, (p < 0.0001). Molecular subtype did not affect the prognosis of OS at stage I and the prognosis of CSS at stages I-II. In multivariate analysis, there was a significantly higher risk of death from BC and from any cause for LB, HR-Her2neu+ and TNBC compared to the LA subtype.
Conclusion. Surrogate molecular biological subtypes of BC in the Russian population are associated with survival prognosis. Further analysis of non-breast cancer-related mortality is needed.
References
Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66. doi:10.1038/s41572-019-0111-2.
Gnant M, Harbeck N, Thomssen C. St. Gallen 2011: Summary of the consensus discussion. breast care (Basel). 2011;6(2):136-141. doi:10.1159/000328054.
Burstein HJ, Curigliano G, Thürlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021;32(10):1216-1235. doi:10.1016/j.annonc.2021.06.023.
Fisusi FA, Akala EO. Drug combinations in breast cancer therapy. Pharm Nanotechnol. 2019;7(1):3-23. doi:10.2174/2211738507666190122111224.
Iwamoto T, Booser D, Valero V, et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol. 2012;30(7):729-34. doi:10.1200/JCO.2011.36.2574.
Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007;25(25):3846-52. doi:10.1200/JCO.2007.11.9453.
McCarthy AM, Friebel-Klingner T, Ehsan S, et al. Relationship of established risk factors with breast cancer subtypes. Cancer Med. 2021;10(18):6456-6467. doi:10.1002/cam4.4158.
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023-1075. doi:10.1016/S0140-6736(17)33326-3.
Barchuk A, Tursun-Zade R, Belayev A, et al. Comparability and validity of cancer registry data in the northwest of Russia. Acta Oncol. 2021;60(10):1264-1271. doi:10.1080/0284186X.2021.1967443.
Агаева А.В., Светлакова А.В., Громов Д.Д. и др. Популяционные факторы прогноза выживаемости при раке молочной железы: анализ по данным Архангельского областного канцер-регистра за 2000–2020 гг. Опухоли женской репродуктивной системы 2023;19(1):00–00 [Agaeva AV, Svetlakova AV, Gromov DD, et al. Population prognostic factors for breast cancer survival: Analysis based on the Arkhangelsk Regional Cancer Registry 2000-2020. Tumors of female reproductive system. 2023;19(1):00–00 (In Russ.)]. doi:10.17650/1994-4098-2023-18-1-00-00.
Франк Г.А., Завалишина Л.Э., Пожарисский К.М. Рак молочной железы. Морфологическая диагностика и генетика. Практическая медицина. 2014:214 [Frank GA, Zavalishina LE, Pozharissky K.M. Breast cancer. Morphological diagnosis and genetics. Practical Medicine. 2014:214 (In Russ.)].
Апанасевич В.И., Артамонова Е.В., Ашрафян Л.А. и др. Золотой стандарт профилактики, диагностики, лечения и реабилитации больных РМЖ 2022. Москва: Издательский дом «АБВ-пресс». 2022:205 [Apanasevich VI, Artamonova EV, Ashrafyan LA, et al. Gold Standard of Prevention, Diagnosis, Treatment and Rehabilitation of Cancer Patients 2022. Moscow: ABV-press Publishing House. 2022:205 (In Russ.)].
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Assoc. 1958;53(282):457–81. doi:10.1080/01621459.1958.10501452.
Cox DR. Regression models and life-tables. journal of the royal statistical society. Series B. 1972;34(2):187–220. Available from: https://www.jstor.org/stable/2985181.
Shah A, Haider G, Abro N, et al. Correlation between age and hormone receptor status in women with breast cancer. Cureus. 2022;14(1):e21652. doi:10.7759/cureus.21652.
Vasconcelos I, Hussainzada A, Berger S, et al. The St. Gallen surrogate classification for breast cancer subtypes successfully predicts tumor presenting features, nodal involvement, recurrence patterns and disease free survival. Breast. 2016;29:181-5. doi:10.1016/j.breast.2016.07.016.
Ehinger A, Malmström P, Bendahl PO, et al. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013. Acta Oncol. 2017;56(1):68-74. doi:10.1080/0284186X.2016.1237778.
Cejalvo JM, Pascual T, Fernández-Martínez A, et al. Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. Cancer Treat Rev. 2018;67:63-70. doi:10.1016/j.ctrv.2018.04.015.
Nelson DR, Brown J, Morikawa A, et al. Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics. PLoS One. 2022;17(2):e0264637. doi:10.1371/journal.pone.0264637.
van Uden DJP, van Maaren MC, Strobbe LJA, et al. Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer. Breast Cancer Res. 2019;21(1):113. doi:10.1186/s13058-019-1201-5.
Prat A, Pineda E, Adamo B, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24(Suppl 2):S26-35. doi:10.1016/j.breast.2015.07.008.
Marczyk VR, Rosa DD, Maia AL, et al. Overall survival for HER2-positive breast cancer patients in the HER2-targeted era: Evidence from a population-based study. Clin Breast Cancer. 2022;22(5):418-423. doi:10.1016/j.clbc.2022.03.004.
Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: Improving patient selection for treatment. Cancer Discov. 2019;9(2):176-198. doi:10.1158/2159-8290.CD-18-1177.
Howlader N, Cronin KA, Kurian AW, et al. Differences in breast cancer survival by molecular subtypes in the united states. Cancer Epidemiol Biomarkers Prev. 2018;27(6):619-626. doi:10.1158/1055-9965.EPI-17-0627.
Johansson ALV, Trewin CB, Hjerkind KV, et al. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort. Int J Cancer. 2019;144(6):1251-1261. doi:10.1002/ijc.31950.
Kast K, Link T, Friedrich K, et al. Impact of breast cancer subtypes and patterns of metastasis on outcome. Breast Cancer Res Treat. 2015;150(3):621-9. doi:10.1007/s10549-015-3341-3.
Gluz O, Graeser M. molecular profiling in early ER + breast cancer to aid systemic therapy decisions. Curr Oncol Rep. 2023;25(5):491–500. doi:10.1007/s11912-023-01377-6.
Валькова Л.Е., Дяченко А.А., Мерабишвили В.М. и др. Влияние пандемии COVID-19 на показатели заболеваемости злокачественными опухолями, подлежащими скринингу в рамках диспансеризации (популяционное исследование) Сибирский онкологический журнал. 2022;21(6):7-16 [Valkova LE, Dyachenko AA, Merabishvili VM, et al. Impact of the СOVID-19 pandemic on cancer incidence in patients undergoing cancer screening during annual health checkup (population-based study). Siberian journal of oncology [Internet]. 2022;21(6):7–16 (In Russ.)]. doi:10.21294/1814-4861-2022-21-6-7-16.
Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013:368(11):987-98. doi:10.1056/NEJMoa1209825.
Bowles EJ, Wellman R, Feigelson HS, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012;104(17):1293-305. doi:10.1093/jnci/djs317.
Sturgeon KM, Deng L, Bluethmann SM, et al. Long-term risk of death from heart disease among breast cancer patients. Front Cardiovasc Med. 2022;9:784409. doi:10.3389/fcvm.2022.784409.
Sturgeon KM, Deng L, Bluethmann SM, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40(48):3889-3897. doi:10.1093/eurheartj/ehz766.
Agha A, Wang X, Wang M, et al. Long-term risk of death from heart disease among breast cancer patients. Front Cardiovasc Med. 2022;9:784409. doi:10.3389/fcvm.2022.784409.
Валькова Л.Е., Левит М.Л., Мерабишвили В.М., и др. Динамика смертности от злокачественных новообразований, регистрируемых в ходе диспансеризации отдельных групп взрослого населения: популяционное исследование по данным архангельского областного канцер-регистра. Research'n Practical Medicine Journal. 2020;7(4):175-182 [Valkova LE, Levit ML, Merabishvili VM, et al. Cancer mortality trends after implementation of the national programme for dispensarization of certain groups of the adult population: a population-based study from arkhangelsk, north-western russia. Research and Practical Medicine Journal. 2020;7(4):175–82 (In Russ.)]. doi:10.17709/2409-2231-2020-7-4-14.
Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206-23. doi:10.1093/annonc/mdt303.
Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160-7. doi:10.1200/JCO.2008.18.1370.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2023